Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.

Ge C, Huang H, Huang F, Yang T, Zhang T, Wu H, Zhou H, Chen Q, Shi Y, Sun Y, Liu L, Wang X, Pearson RB, Cao Y, Kang J, Fu C.

Proc Natl Acad Sci U S A. 2019 Sep 5. pii: 201908998. doi: 10.1073/pnas.1908998116. [Epub ahead of print]

2.

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.

3.

Exploring Perspectives on Antimicrobial Use in Livestock: A Mixed-Methods Study of UK Pig Farmers.

Coyne LA, Latham SM, Dawson S, Donald IJ, Pearson RB, Smith RF, Williams NJ, Pinchbeck GL.

Front Vet Sci. 2019 Aug 2;6:257. doi: 10.3389/fvets.2019.00257. eCollection 2019.

4.

A functional genetic screen defines the AKT-induced senescence signaling network.

Chan KT, Blake S, Zhu H, Kang J, Trigos AS, Madhamshettiwar PB, Diesch J, Paavolainen L, Horvath P, Hannan RD, George AJ, Sanij E, Hannan KM, Simpson KJ, Pearson RB.

Cell Death Differ. 2019 Jul 8. doi: 10.1038/s41418-019-0384-8. [Epub ahead of print]

PMID:
31285545
5.

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ.

Cancer Discov. 2019 Aug;9(8):1036-1049. doi: 10.1158/2159-8290.CD-18-1455. Epub 2019 May 15.

PMID:
31092402
6.

Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer.

Trigos AS, Pearson RB, Papenfuss AT, Goode DL.

Elife. 2019 Feb 26;8. pii: e40947. doi: 10.7554/eLife.40947.

7.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2:39. doi: 10.1038/s42003-019-0284-y. eCollection 2019.

8.

A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.

Somers K, Wen VW, Middlemiss SMC, Osborne B, Forgham H, Jung M, Karsa M, Clifton M, Bongers A, Gao J, Mayoh C, Raoufi-Rad N, Kusnadi EP, Hannan KM, Scott DA, Kwek A, Liu B, Flemming C, Chudakova DA, Pandher R, Failes TW, Lim J, Angeli A, Osterman AL, Imamura T, Kees UR, Supuran CT, Pearson RB, Hannan RD, Davis TP, McCarroll J, Kavallaris M, Turner N, Gudkov AV, Haber M, Norris MD, Henderson MJ.

Oncogene. 2019 May;38(20):3824-3842. doi: 10.1038/s41388-018-0666-5. Epub 2019 Jan 22.

PMID:
30670779
9.

Antimicrobial use practices, attitudes and responsibilities in UK farm animal veterinary surgeons.

Coyne LA, Latham SM, Dawson S, Donald IJ, Pearson RB, Smith RF, Williams NJ, Pinchbeck GL.

Prev Vet Med. 2018 Dec 1;161:115-126. doi: 10.1016/j.prevetmed.2018.10.021. Epub 2018 Oct 30.

10.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.

Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.

11.

Cystathionine β-Synthase in Physiology and Cancer.

Zhu H, Blake S, Chan KT, Pearson RB, Kang J.

Biomed Res Int. 2018 Jun 28;2018:3205125. doi: 10.1155/2018/3205125. eCollection 2018. Review.

12.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
13.

Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers.

Udugama M, Sanij E, Voon HPJ, Son J, Hii L, Henson JD, Chan FL, Chang FTM, Liu Y, Pearson RB, Kalitsis P, Mann JR, Collas P, Hannan RD, Wong LH.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4737-4742. doi: 10.1073/pnas.1720391115. Epub 2018 Apr 18.

14.

How the evolution of multicellularity set the stage for cancer.

Trigos AS, Pearson RB, Papenfuss AT, Goode DL.

Br J Cancer. 2018 Jan;118(2):145-152. doi: 10.1038/bjc.2017.398. Epub 2018 Jan 16. Review.

15.

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.

Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.

16.

Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.

Darido C, Georgy SR, Cullinane C, Partridge DD, Walker R, Srivastava S, Roslan S, Carpinelli MR, Dworkin S, Pearson RB, Jane SM.

Cell Death Differ. 2018 Jun;25(6):1146-1159. doi: 10.1038/s41418-017-0032-0. Epub 2017 Dec 13.

17.

Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors.

Trigos AS, Pearson RB, Papenfuss AT, Goode DL.

Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):6406-6411. doi: 10.1073/pnas.1617743114. Epub 2017 May 8.

18.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.

19.

Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.

Rebello RJ, Pearson RB, Hannan RD, Furic L.

Genes (Basel). 2017 Feb 16;8(2). pii: E71. doi: 10.3390/genes8020071. Review.

20.

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.

Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E.

Int J Mol Sci. 2017 Jan 20;18(1). pii: E210. doi: 10.3390/ijms18010210. Review.

21.

Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription.

Hung SS, Lesmana A, Peck A, Lee R, Tchoubrieva E, Hannan KM, Lin J, Sheppard KE, Jastrzebski K, Quinn LM, Rothblum LI, Pearson RB, Hannan RD, Sanij E.

Gene. 2017 May 15;612:36-48. doi: 10.1016/j.gene.2016.12.015. Epub 2016 Dec 15.

PMID:
27989772
22.

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.

Clin Cancer Res. 2017 Apr 1;23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. Epub 2016 Sep 23.

23.

Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence.

Chan KT, Paavolainen L, Hannan KM, George AJ, Hannan RD, Simpson KJ, Horvath P, Pearson RB.

Assay Drug Dev Technol. 2016 Sep;14(7):416-28. doi: 10.1089/adt.2016.739.

PMID:
27552145
24.

Understanding the culture of antimicrobial prescribing in agriculture: a qualitative study of UK pig veterinary surgeons.

Coyne LA, Latham SM, Williams NJ, Dawson S, Donald IJ, Pearson RB, Smith RF, Pinchbeck GL.

J Antimicrob Chemother. 2016 Nov;71(11):3300-3312. Epub 2016 Aug 11.

25.

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.

Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L, Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L.

Clin Cancer Res. 2016 Nov 15;22(22):5539-5552. doi: 10.1158/1078-0432.CCR-16-0124. Epub 2016 Aug 2.

26.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

27.

Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription.

Kang J, Kusnadi EP, Ogden AJ, Hicks RJ, Bammert L, Kutay U, Hung S, Sanij E, Hannan RD, Hannan KM, Pearson RB.

Oncotarget. 2016 Aug 2;7(31):48887-48904. doi: 10.18632/oncotarget.10346.

28.

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, Sanij E, Kang J, Drygin D, O'Brien S, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Cancer Discov. 2016 Jan;6(1):59-70. doi: 10.1158/2159-8290.CD-14-0673. Epub 2015 Oct 21.

29.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024
30.

S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila.

Mitchell NC, Tchoubrieva EB, Chahal A, Woods S, Lee A, Lin JI, Parsons L, Jastrzebski K, Poortinga G, Hannan KM, Pearson RB, Hannan RD, Quinn LM.

Cell Signal. 2015 Oct;27(10):2045-53. doi: 10.1016/j.cellsig.2015.07.018. Epub 2015 Jul 26.

PMID:
26215099
31.

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL.

Mol Cancer Ther. 2015 Jun;14(6):1495-503. doi: 10.1158/1535-7163.MCT-15-0039. Epub 2015 Apr 7. Erratum in: Mol Cancer Ther. 2017 Mar;16(3):551.

32.

Unexpected role of CDK4 in a G2/M checkpoint.

Sheppard KE, Pearson RB, Hannan RD.

Cell Cycle. 2015;14(9):1351-2. doi: 10.1080/15384101.2015.1022060. No abstract available.

33.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1340. doi: 10.1038/onc.2014.460. No abstract available.

PMID:
25740609
34.

The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.

Woods SJ, Hannan KM, Pearson RB, Hannan RD.

Biochim Biophys Acta. 2015 Jul;1849(7):821-9. doi: 10.1016/j.bbagrm.2014.10.007. Epub 2014 Nov 11. Review.

PMID:
25464032
35.

A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.

Sanij E, Diesch J, Lesmana A, Poortinga G, Hein N, Lidgerwood G, Cameron DP, Ellul J, Goodall GJ, Wong LH, Dhillon AS, Hamdane N, Rothblum LI, Pearson RB, Haviv I, Moss T, Hannan RD.

Genome Res. 2015 Feb;25(2):201-12. doi: 10.1101/gr.176115.114. Epub 2014 Dec 1.

36.

Regulation of rDNA transcription in response to growth factors, nutrients and energy.

Kusnadi EP, Hannan KM, Hicks RJ, Hannan RD, Pearson RB, Kang J.

Gene. 2015 Feb 1;556(1):27-34. doi: 10.1016/j.gene.2014.11.010. Epub 2014 Nov 8. Review.

PMID:
25447905
37.

Understanding antimicrobial use and prescribing behaviours by pig veterinary surgeons and farmers: a qualitative study.

Coyne LA, Pinchbeck GL, Williams NJ, Smith RF, Dawson S, Pearson RB, Latham SM.

Vet Rec. 2014 Dec 13;175(23):593. doi: 10.1136/vr.102686. Epub 2014 Sep 8.

PMID:
25200432
38.

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.

Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS.

PLoS One. 2014 Mar 21;9(3):e88950. doi: 10.1371/journal.pone.0088950. eCollection 2014.

39.

PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.

Gilan O, Diesch J, Amalia M, Jastrzebski K, Chueh AC, Verrills NM, Pearson RB, Mariadason JM, Tulchinsky E, Hannan RD, Dhillon AS.

Oncogene. 2015 Mar 5;34(10):1333-9. doi: 10.1038/onc.2014.26. Epub 2014 Mar 17. Erratum in: Oncogene. 2015 Mar 5;34(10):1340.

PMID:
24632621
40.

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, Pearson RB, Christensen JG, Randolph S, McArthur GA, Sheppard KE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):590-600. doi: 10.1111/pcmr.12228. Epub 2014 Mar 6.

PMID:
24495407
41.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.

42.

Targeting the nucleolus for cancer intervention.

Quin JE, Devlin JR, Cameron D, Hannan KM, Pearson RB, Hannan RD.

Biochim Biophys Acta. 2014 Jun;1842(6):802-16. doi: 10.1016/j.bbadis.2013.12.009. Epub 2014 Jan 2. Review.

43.

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.

Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.

PMID:
24011934
44.

AKT-independent PI3-K signaling in cancer - emerging role for SGK3.

Bruhn MA, Pearson RB, Hannan RD, Sheppard KE.

Cancer Manag Res. 2013 Aug 26;5:281-92. doi: 10.2147/CMAR.S35178. eCollection 2013. Review.

45.

Targeting RNA polymerase I transcription and the nucleolus for cancer therapy.

Hannan RD, Drygin D, Pearson RB.

Expert Opin Ther Targets. 2013 Aug;17(8):873-8. doi: 10.1517/14728222.2013.818658.

PMID:
23862680
46.

Akt1 is the principal Akt isoform regulating apoptosis in limiting cytokine concentrations.

Green BD, Jabbour AM, Sandow JJ, Riffkin CD, Masouras D, Daunt CP, Salmanidis M, Brumatti G, Hemmings BA, Guthridge MA, Pearson RB, Ekert PG.

Cell Death Differ. 2013 Oct;20(10):1341-9. doi: 10.1038/cdd.2013.63. Epub 2013 Jun 21.

47.

Dysregulation of the basal RNA polymerase transcription apparatus in cancer.

Bywater MJ, Pearson RB, McArthur GA, Hannan RD.

Nat Rev Cancer. 2013 May;13(5):299-314. doi: 10.1038/nrc3496. Review.

PMID:
23612459
48.

Autophagy induction is a Tor- and Tp53-independent cell survival response in a zebrafish model of disrupted ribosome biogenesis.

Boglev Y, Badrock AP, Trotter AJ, Du Q, Richardson EJ, Parslow AC, Markmiller SJ, Hall NE, de Jong-Curtain TA, Ng AY, Verkade H, Ober EA, Field HA, Shin D, Shin CH, Hannan KM, Hannan RD, Pearson RB, Kim SH, Ess KC, Lieschke GJ, Stainier DY, Heath JK.

PLoS Genet. 2013;9(2):e1003279. doi: 10.1371/journal.pgen.1003279. Epub 2013 Feb 7.

49.

Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.

Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, Ralli R, Cullinane C, Schmitt CA, Reimann M, Hall MN, Wall M, Hannan RD, Pearson RB, McArthur GA, Johnstone RW.

Blood. 2013 Apr 11;121(15):2964-74. doi: 10.1182/blood-2012-08-446096. Epub 2013 Feb 12.

50.

Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.

Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson KJ.

Clin Cancer Res. 2013 Mar 15;19(6):1411-21. doi: 10.1158/1078-0432.CCR-12-3433. Epub 2013 Jan 29.

Supplemental Content

Loading ...
Support Center